Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 19/20 | 0.53 |
| ▸ | CCNE1 | P24864 | 17/20 | 0.53 |
| ▸ | CCND1 | P24385 | 16/20 | 0.53 |
| ▸ | CDK6 | Q00534 | 14/20 | 0.53 |
| ▸ | JUN | P05412 | 1/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.52 |
| ▸ | CDK4 | P11802 | 5/20 | 0.48 |
| ▸ | CDK1 | P06493 | 2/20 | 0.48 |
| ▸ | CCND3 | P30281 | 1/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.45 |
| ▸ | CDK9 | P50750 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL558334 | 1.00 | CDK2 (0.53) | CDK2CCNE1CCND1CDK6JUN | |
| SCHEMBL10166128 | 0.84 | MAPK10 (0.52) | CDK2CCNE1CCND1CDK6JUN | |
| SCHEMBL30804793 | 0.83 | CDK2 (0.58) | CDK2CCNE1CCND1CDK6CDK4 | |
| SCHEMBL27061752 | 0.83 | CDK2 (0.58) | CDK2CCNE1CCND1CDK6CDK4 | |
| SCHEMBL559554 | 0.82 | MAPK10 (0.50) | CDK2CCNE1CCND1CDK6JUN | |
| SCHEMBL559555 | 0.82 | MAPK10 (0.50) | CDK2CCNE1CCND1CDK6JUN | |
| SCHEMBL14391744 | 0.82 | MAPK10 (0.52) | CDK2CCNE1CCND1CDK6JUN | |
| SCHEMBL27061977 | 0.81 | CDK2 (0.56) | CDK2CCNE1CCND1CDK6JUN | |
| SCHEMBL30726225 | 0.78 | CDK2 (0.51) | CDK2CCNE1CCND1CDK6CDK4 | |
| SCHEMBL27033439 | 0.78 | CDK2 (0.51) | CDK2CCNE1CCND1CDK6CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-7998978-B2 | Substituted 2-amino-fused heterocyclic compounds | PFIZER INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| EP-2024342-A2 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | Pfizer Products Incorporated (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007125405-A2 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | CDK2 125/4885CCNE1 523/4885CCND1 762/4885 |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | CDK2 125/4885CCNE1 523/4885CCND1 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.